Tirzepatide is a dual incretin receptor agonist combining GIP receptor (GIPR) and GLP-1 receptor (GLP-1R) activity in a single peptide molecule. Its twin-incretin mechanism activates both pancreatic and extrapancreatic GIPR and GLP-1R signaling pathways simultaneously, producing metabolic effects that have been shown to exceed those of GLP-1 mono-agonism in both preclinical and clinical settings. Tirzepatide’s co-agonism is studied for its ability to engage complementary intracellular signaling cascades — including cAMP and beta-arrestin pathways — in ways that may amplify individual receptor responses.

Preclinical research has examined Tirzepatide’s effects on adipose tissue remodeling, hepatic lipid metabolism, pancreatic islet morphology, and hypothalamic appetite signaling. Clinical research data has demonstrated significant metabolic and glycemic (HbA1c) changes in large randomized controlled trials, establishing it as a benchmark compound for evaluating new metabolic therapeutics. Studies have also investigated its cardiovascular protective effects, including reductions in blood pressure, triglycerides, and inflammatory markers in research subjects.

This 20mg concentration is intended for research protocols requiring larger quantities of Tirzepatide, such as extended preclinical studies, multi-dosing cohort designs, or large animal pharmacokinetic research. Tirzepatide is a standard reference compound in dual incretin receptor agonist research and is widely cited across metabolic disease and endocrinology research literature.

Disclaimer: This product is intended for in vitro research and laboratory use only. It is not intended for human or veterinary use, consumption, or injection. Not approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. For use by qualified researchers only.